ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
Corcept Therapeutics Incorporated Q3 2026 Earnings Call Summary
Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173
Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) Q3 EPS Beat Offset by In-Line Revenue and Reiterated Guidance
Corcept Therapeutics falls on guidance despite earnings beat
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
Corcept: Q3 Earnings Snapshot
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics Q3 2026 Earnings Call Transcript
Corcept Therapeutics Affirms FY2026 Sales Guidance of $1.100B-$1.200B vs $1.146B Est
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
What Corcept Therapeutics Stock Positive Trial Results Mean For Shareholders
Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.